Dendreon Corporation (Nasdaq: DNDN) announced that its pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE